Pentostatin and cyclophosphamide: An effective new regimen in previously treated patients with chronic lymphocytic leukemia

Journal of Clinical Oncology

Volumn 21, Issue 7, 2003, Pages 1278-1284

  Weiss, Mark A ^a   Maslak, Peter G ^a   Jurcic, Joseph G ^a   Scheinberg, David A ^a   Aliff, Timothy B ^a   Lamanna, Nicole ^a   Frankel, Stanley R ^a   Kossman, Steven E ^a   Horgan, Denise ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CHLORAMBUCIL; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; FLUDARABINE; PENTOSTATIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; VIDARABINE;

ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HUMAN; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; ADULT; AGED; BONE MARROW; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; DRUG EFFECT; DRUG RESISTANCE; FEMALE; MALE; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; MIDDLE AGED; NEUTROPENIA; PENTOSTATIN; THROMBOCYTOPENIA; TREATMENT OUTCOME; VIDARABINE;

EID: 0038514130     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.08.100     Document Type: Article

References (29)

1. Dighiero G, Travade P, Chevret S, et al: B-cell chronic lymphocytic leukemia: Present status and future directions. Blood 78:1901-1914, 1991
2. O'Brien S, del Giglio A, Keating M: Review article: Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. Blood 85:307-318, 1995
3. Rai KR, Peterson BL, Appelbaum FR, et al: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343:1750-1757, 2000
4. Grever MR, Kopecky KJ, Coltman CA, et al: Fludarabine monophosphate: A potentially useful agent in chronic lymphocytic leukemia. Nouv Rev Fr Hematol 30:457-459, 1988
5. Keating MJ, Kantarjian H, Talpaz M, et al: Fludarabine: A new agent with major activity against chronic lymphocytic leukemia. Blood 74:19-25, 1989
6. Juliusson G, Liliemark J: High complete remission rate from 2-chloro-2′-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: Response predicted by rapid decease of blood lymphocyte count. J Clin Oncol 11:679-689, 1993
7. Saven A, Lemon RH, Kosty M, et al: 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol 13:570-574, 1995
8. Grever MR, Leiby JM, Kraut EH, et al: Low-dose deoxycoformycin in lymphoid malignancy. J Clin Oncol 3:1196-1201, 1985
9. Dillman RO, Mick R, McIntyre OR: Pentostatin in chronic lymphocytic leukemia: A phase II trial of Cancer and Leukemia Group B. J Clin Oncol 7:433-438, 1989
10. Keating MJ, Kantarjian H, O'Brien S, et al: Fludarabine: A new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol 9:44-49, 1991
11. Keating MJ, O'Brien S, Kantarjian H, et al: Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 81:2878-2884, 1993
12. Anaissie E, Kontoyiannis DP, Kantarjian H, et al: Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone. Ann Intern Med 117:466-469, 1992
13. O'Brien S, Kantarjian H, Beran M, et al: Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 82:1695-1700, 1993
14. Elias L, Stock-Novack D, Head DR, et al: A phase I trial of combination fludarabine monophosphate and chlorambucil in chronic lymphocytic leukemia: A Southwest Oncology Group study. Leukemia 7:361-365, 1993
15. Weiss M, Spiess T, Berman E, et al: Concomitant administration of chlorambucil limits dose intensity of fludarabine in previously treated patients with chronic lymphocytic leukemia. Leukemia 8:1290-1293, 1994
16. Flinn I, Byrd J, Morrison C, et al: Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood 96:71-75, 2000
17. Weiss M, Glenn M, Maslak P, et al: Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy. Leukemia 14:1557-1582, 2000
18. O'Brien SM, Kantarjian HM, Cortes J, et al: Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 19:1414-1420, 2001
19. Spiers AS, Moore D, Cassileth PA, et al: Remissions in hairy-cell leukemia with pentostatin (2′-deoxycoformycin). N Engl J Med 316:825-830, 1987
20. Grever MR, Chapman RA, Ratanandotharathorn V, Siease RB. An investigation of deoxycoformycin in advanced cutaneous T-cell lymphoma. Blood 66:215a, 1986 (suppl 1, abstr 744)
21. Johnston JB, Verburg L, Shore T, et al: Combination therapy with nucleoside analogs and alkylating agents. Leukemia 8:S140-S143, 1994 (suppl)
22. Cheson BD, Bennett JM, Grever M, et al: National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 87: 4990-4997, 1996
23. National Cancer Institute: Common Toxicity Criteria. Bethesda, MD, Division of Cancer Treatment, National Cancer Institute, 1988
24. Robertson LE, Huh YO, Butler JJ, et al: Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: Clinical, immunophenotypic, and molecular analysis. Blood 80:29-36, 1992
25. Flinn IW, Kopecky KJ, Foucar MK, et al: Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 96:2981-2986, 2000
26. Margolis J, Grever MR: Pentostatin (Nipent): A review of potential toxicity and its management. Semin Oncol 27:9-14, 2000 (suppl 5)
27. Keating M, O'Brien S, Lerner S, et al: Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 92:1165-1171, 1988
28. Parkins JG, Flynn JM, Howard RS, et al: Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: Implications for clinical trials in this patient population. Cancer 94:2033-2039, 2002
29. Keating MJ, Flinn I, Jain V, et al: Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99:3554-3561, 2002